Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus radiation with nivolumab vs placebo in newly diagnosed MGMT-methylated glioblastoma
2015-004722-34Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in glioblastoma (GBM) comparing Nivolumab + temozolomide + radiation with Placebo + temozolomide + radiation (2 arms). Primary endpoint: Progression-free survival. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2015-004722-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004722-34.